Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mfs Pharmaceuticals Limited has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 examiner and 1 art unit, providing a single point of focus for prosecution management.
DAHLIN, HEATHER RAQUEL is the busiest examiner, with 1 pending matter. A practitioner can concentrate on the particular examiner's approach and the applicable art-unit context when preparing the response. The available data does not identify the claims at issue, the cited references, or the procedural status beyond the pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19124744 | Pharmaceutical Combinations for Treatment | DAHLIN, HEATHER RAQUEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19124744 | Pharmaceutical Combinations for Treatment | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19124744 | Pharmaceutical Combinations for Treatment | DAHLIN, HEATHER RAQUEL | 1629 | §102§103 | Final Rejection | — | Pending | Apr 25, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMfs Pharmaceuticals Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Heather Raquel Dahlin has the most, with 1 of Mfs Pharmaceuticals Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
